ADMA Biologics (ADMA) Competitors $23.80 -0.31 (-1.29%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADMA vs. TEVA, ITCI, GMAB, RDY, ASND, MRNA, VTRS, QGEN, ROIV, and LNTHShould you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include Teva Pharmaceutical Industries (TEVA), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. ADMA Biologics vs. Teva Pharmaceutical Industries Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Lantheus ADMA Biologics (NASDAQ:ADMA) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk. Which has preferable earnings & valuation, ADMA or TEVA? ADMA Biologics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M13.26-$28.24M$0.8229.02Teva Pharmaceutical Industries$16.54B1.06-$1.64B-$1.45-10.70 Does the MarketBeat Community believe in ADMA or TEVA? Teva Pharmaceutical Industries received 921 more outperform votes than ADMA Biologics when rated by MarketBeat users. However, 72.13% of users gave ADMA Biologics an outperform vote while only 67.84% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformADMA BiologicsOutperform Votes41472.13% Underperform Votes16027.87% Teva Pharmaceutical IndustriesOutperform Votes133567.84% Underperform Votes63332.16% Which has more risk and volatility, ADMA or TEVA? ADMA Biologics has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500. Do analysts rate ADMA or TEVA? ADMA Biologics presently has a consensus price target of $22.50, indicating a potential downside of 5.46%. Teva Pharmaceutical Industries has a consensus price target of $23.43, indicating a potential upside of 51.05%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than ADMA Biologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Is ADMA or TEVA more profitable? ADMA Biologics has a net margin of 17.80% compared to Teva Pharmaceutical Industries' net margin of -9.91%. ADMA Biologics' return on equity of 53.20% beat Teva Pharmaceutical Industries' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics17.80% 53.20% 26.07% Teva Pharmaceutical Industries -9.91%42.46%6.65% Does the media favor ADMA or TEVA? In the previous week, ADMA Biologics had 3 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 22 mentions for ADMA Biologics and 19 mentions for Teva Pharmaceutical Industries. ADMA Biologics' average media sentiment score of 1.24 beat Teva Pharmaceutical Industries' score of 1.23 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 15 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Teva Pharmaceutical Industries 14 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in ADMA or TEVA? 75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryADMA Biologics beats Teva Pharmaceutical Industries on 14 of the 19 factors compared between the two stocks. Get ADMA Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADMA vs. The Competition Export to ExcelMetricADMA BiologicsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.66B$3.00B$5.57B$7.83BDividend YieldN/A1.89%5.11%4.22%P/E Ratio85.0030.4222.4418.48Price / Sales13.26498.92394.09103.59Price / Cash311.70168.6838.1834.62Price / Book39.673.206.774.25Net Income-$28.24M-$72.35M$3.22B$248.23M7 Day Performance6.58%1.46%1.49%0.89%1 Month Performance22.55%8.79%4.00%3.53%1 Year Performance256.82%-22.36%16.21%5.08% ADMA Biologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADMAADMA Biologics1.4801 of 5 stars$23.80-1.3%$22.50-5.5%+265.0%$5.66B$426.45M85.00530Upcoming EarningsNews CoveragePositive NewsGap DownTEVATeva Pharmaceutical Industries3.2638 of 5 stars$13.30-2.6%$23.43+76.2%+10.5%$15.08B$16.54B-9.1736,800Upcoming EarningsAnalyst RevisionPositive NewsITCIIntra-Cellular Therapies0.8812 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560Upcoming EarningsAnalyst ForecastGMABGenmab A/S4.4508 of 5 stars$20.07+0.1%$39.17+95.2%-23.6%$13.28B$21.53B11.531,660Upcoming EarningsAnalyst RevisionRDYDr. Reddy's Laboratories1.8436 of 5 stars$13.68+0.1%$17.00+24.3%-5.3%$11.42B$311.31B21.7824,800Upcoming EarningsASNDAscendis Pharma A/S2.3344 of 5 stars$161.15-2.4%$204.67+27.0%+23.1%$9.83B$363.64M-22.70640Positive NewsMRNAModerna4.3453 of 5 stars$25.13+1.7%$58.70+133.6%-74.1%$9.72B$3.20B-2.713,900VTRSViatris1.8348 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6786 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.1666 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860LNTHLantheus3.9823 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsPositive News Related Companies and Tools Related Companies TEVA Alternatives ITCI Alternatives GMAB Alternatives RDY Alternatives ASND Alternatives MRNA Alternatives VTRS Alternatives QGEN Alternatives ROIV Alternatives LNTH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADMA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADMA Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ADMA Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADMA Stock Free ADMA Stock Alerts